InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada. The company focuses on researching and developing cannabinoid-based pharmaceutical products targeting diseases with high unmet medical needs, particularly in dermatology, ophthalmology, and neurodegenerative disorders. Its lead product candidate, INM-755, is a cannabinol-based topical cream for epidermolysis bullosa, having completed Phase 2 clinical trials. Additional pipeline assets include INM-089, a small molecule selective dual CB1/CB2 agonist for dry age-related macular degeneration, and INM-901 for Alzheimer’s disease, demonstrating preclinical neuroprotective and anti-neuroinflammatory effects. InMed Pharmaceuticals Inc. also develops IntegraSyn, a proprietary biosynthesis-based manufacturing system for pharmaceutical-grade cannabinoids. Previously operating a commercial segment through subsidiary BayMedica producing rare cannabinoids for the health and wellness industry, the company is now concentrating exclusively on advancing its pharmaceutical pipeline toward IND filings and clinical trials. Operating in the healthcare sector, specifically drug manufacturers specializing in novel cannabinoid therapies, InMed Pharmaceuticals Inc. contributes to innovative treatments leveraging cannabinoid science.